ArticleJournal of thoracic disease2025
Fractional exhaled nitric oxide (FeNO) in chronic obstructive respiratory diseases is associated with the bronchodilator response.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Among chronic obstructive respiratory diseases (CORDs), the fractional exhaled nitric oxide (FeNO) is a marker of eosinophilic airway inflammation. Few data on FeNO in CORD are available in Vietnam. In this study, we aimed to relate the FeNO with the clinical and functional characteristics of CORD in Vietnam. Methods: A cross-sectional study was conducted in 235 patients with chronic respiratory symptoms and airways limitation. Clinical evaluation was obtained by questionnaire; pre- and post-bronchodilator (BD) spirometry, eosinophil counts, allergen skin tests and FeNO were measured. Patients were considered as chronic obstructive pulmonary disease (COPD), asthmatics or asthma COPD overlap (ACO) based on GINA/GOLD guidelines. The FeNO levels were related to clinical, spirometric and inflammatory parameters. Results: They were 93 COPD, 93 ACO and 49 asthmatics. The concentration of FeNO was high (≥25 ppb) in 69.4% asthmatics, 55.9% of ACO and 34.4% COPD. A high FeNO was more frequent among women, younger, asthmatics, former- or non-smokers, low severity (fewer exacerbations and lower airways limitation), BD responsiveness and type 2 (T2) inflammation [history of allergy, elevated blood eosinophils count (BEC), positive skin tests]. A low FeNO was more frequent in patients with X-ray emphysema or history of tuberculosis. The FeNO level correlated positively with the blood eosinophils and the BD responsiveness in non-smokers but negatively with the basal level of airflow limitation. Conclusions: In Vietnamese non-smokers with chronic obstructive respiratory disease, FeNO is a type 2 biomarker and a significant predictor of BD responsiveness. We hypothesized that this might predict the response to inhaled corticosteroids (ICS).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.